Brainstorm Cell Therapeutics Inc
BCLI1.170USD
0.0000.00%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
9.26MCap. mercado
PérdidaP/E TTM
Más Datos de Brainstorm Cell Therapeutics Inc Compañía
BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.
Información de Brainstorm Cell Therapeutics Inc
Símbolo de cotizaciónBCLI
Nombre de la empresaBrainstorm Cell Therapeutics Inc
Fecha de salida a bolsaMay 28, 2003
Director ejecutivoMr. Chaim Lebovits
Número de empleados27
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 28
Dirección1325 Avenue Of Americas
CiudadNEW YORK
Bolsa de valoresUS 'Other OTC' and Grey Market
PaísUnited States of America
Código postal10019
Teléfono12014880460
Sitio Webhttps://brainstorm-cell.com/
Símbolo de cotizaciónBCLI
Fecha de salida a bolsaMay 28, 2003
Director ejecutivoMr. Chaim Lebovits
Ejecutivos de Brainstorm Cell Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Uri Yablonka
Mr. Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Director, Executive Vice President, Chief Business Officer, Secretary
68.46K
--
Dr. Hartoun Hartounian, Ph.D.
Dr. Hartoun Hartounian, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
52.00K
--
Ms. Alla Patlis, CPA
Ms. Alla Patlis, CPA
Interim Chief Financial Officer, Controller
Interim Chief Financial Officer, Controller
44.35K
+919.54%
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
Director
Director
44.15K
--
Dr. Irit Arbel, Ph.D.
Dr. Irit Arbel, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
41.05K
--
Mr. Nir Naor, CPA
Mr. Nir Naor, CPA
Independent Director
Independent Director
31.47K
+3833.25%
Dr. Ibrahim B. (Bob) Dagher, M.D.
Dr. Ibrahim B. (Bob) Dagher, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Prof. Jacob A. Frenkel, Ph.D.
Prof. Jacob A. Frenkel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Menghisteab (Menghis) Bairu, M.D.
Dr. Menghisteab (Menghis) Bairu, M.D.
Independent Director
Independent Director
--
--
Dr. Anthony John (Tony) Polverino, Ph.D.
Dr. Anthony John (Tony) Polverino, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Uri Yablonka
Mr. Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Director, Executive Vice President, Chief Business Officer, Secretary
68.46K
--
Dr. Hartoun Hartounian, Ph.D.
Dr. Hartoun Hartounian, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
52.00K
--
Ms. Alla Patlis, CPA
Ms. Alla Patlis, CPA
Interim Chief Financial Officer, Controller
Interim Chief Financial Officer, Controller
44.35K
+919.54%
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
Director
Director
44.15K
--
Dr. Irit Arbel, Ph.D.
Dr. Irit Arbel, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
41.05K
--
Mr. Nir Naor, CPA
Mr. Nir Naor, CPA
Independent Director
Independent Director
31.47K
+3833.25%
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: hace 6 horas
Actualizado: hace 6 horas
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Ruck (Matthew J)
2.50%
Lebovits Chaim
1.82%
ACC International Holdings, Ltd.
1.21%
Dagher (Ibrahim B.)
0.72%
Yablonka (Uri)
0.62%
Otro
93.13%
Accionistas
Accionistas
Proporción
Ruck (Matthew J)
2.50%
Lebovits Chaim
1.82%
ACC International Holdings, Ltd.
1.21%
Dagher (Ibrahim B.)
0.72%
Yablonka (Uri)
0.62%
Otro
93.13%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
8.44%
Holding Company
1.21%
Investment Advisor
0.02%
Otro
90.33%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
81
2.42K
0.02%
-1.20M
2025Q3
92
137.97K
1.25%
-1.09M
2025Q2
115
2.33M
29.32%
+762.13K
2025Q1
116
2.29M
28.90%
+743.86K
2024Q4
114
1.19M
21.02%
-226.10K
2024Q3
109
1.22M
22.61%
-265.31K
2024Q2
109
1.32M
25.54%
+439.02K
2024Q1
108
855.32K
19.26%
-132.87K
2023Q4
109
841.70K
26.44%
-125.02K
2023Q3
116
902.82K
33.14%
-178.28K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Ruck (Matthew J)
275.84K
2.5%
+275.84K
--
Nov 13, 2024
Lebovits Chaim
200.96K
1.82%
--
--
Apr 01, 2025
ACC International Holdings, Ltd.
133.39K
1.21%
--
--
Apr 01, 2025
Dagher (Ibrahim B.)
79.52K
0.72%
--
--
Apr 01, 2025
Yablonka (Uri)
68.46K
0.62%
--
--
Apr 01, 2025
Hartounian (Hartoun)
52.00K
0.47%
--
--
Apr 01, 2025
Patlis (Alla)
44.35K
0.4%
+40.00K
+919.54%
Jan 01, 2025
Lindborg (Stacy R)
44.15K
0.4%
--
--
Apr 01, 2025
Frenkel (Jacob A.)
43.78K
0.4%
--
--
Apr 01, 2025
Arbel (Irit)
41.05K
0.37%
--
--
Apr 01, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
Sep 26, 2024
Merger
15→1
